Volume | 301,021 |
|
|||||
News | (1) | ||||||
Day High | 3.61 | Low High |
|||||
Day Low | 3.39 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Repare Therapeutics Inc | RPTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.49 | 3.39 | 3.61 | 3.53 | 3.52 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,079 | 301,021 | US$ 3.49 | US$ 1,051,032 | - | 2.98 - 13.85 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:50:07 | formt | 150 | US$ 3.64 | USD |
Repare Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
149.75M | 42.18M | - | 51.13M | -93.8M | -2.22 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Repare Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPTX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.15 | 3.70 | 3.03 | 3.37 | 187,987 | 0.49 | 15.56% |
1 Month | 3.39 | 3.96 | 3.03 | 3.64 | 473,173 | 0.25 | 7.37% |
3 Months | 5.32 | 5.66 | 2.98 | 3.73 | 228,549 | -1.68 | -31.58% |
6 Months | 5.22 | 8.49 | 2.98 | 5.27 | 213,529 | -1.58 | -30.27% |
1 Year | 11.36 | 13.85 | 2.98 | 6.04 | 216,437 | -7.72 | -67.96% |
3 Years | 31.88 | 35.75 | 2.98 | 13.02 | 239,152 | -28.24 | -88.58% |
5 Years | 32.05 | 46.44 | 2.98 | 15.81 | 213,181 | -28.41 | -88.64% |
Repare Therapeutics Description
Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. |